Residency · Residency · Radiation Oncology

Nasopharyngeal Carcinoma: Concurrent Chemoradiation and IMRT Technique

Overview

Nasopharyngeal carcinoma (NPC) is a distinct malignancy of the head and neck region characterized by unique epidemiological patterns, etiological factors, and treatment strategies. Radiation therapy serves as the primary treatment modality because of the tumor’s deep anatomical location and its high radiosensitivity. The advent of intensity-modulated radiation therapy (IMRT) has significantly improved clinical outcomes by allowing the delivery of high radiation doses to the skull base while sparing critical structures such as the parotid glands and temporal lobes. For locoregionally advanced NPC (stages II to IVA), concurrent cisplatin-based chemoradiation remains the standard of care.

Epidemiology and Etiology

NPC is endemic in certain geographic regions, notably southern China, Southeast Asia, and North Africa, where the incidence ranges from 20 to 50 cases per 100,000 people. In contrast, Western countries report a much lower incidence, typically less than 1 per 100,000. A strong etiological association exists between NPC and Epstein-Barr virus (EBV), especially in the non-keratinizing histologic subtypes. Plasma EBV DNA levels serve as a powerful biomarker for prognosis and disease monitoring. Additional risk factors include EBV infection itself, genetic susceptibility linked to specific HLA subtypes, consumption of salted fish, and smoking. The disease most commonly presents between 40 and 60 years of age and exhibits a male predominance with a ratio of approximately 2 to 3 males for every female affected.

WHO Classification

The World Health Organization classifies NPC into three main histologic types. Type I is keratinizing squamous cell carcinoma (SCC), accounting for about 5% of cases in endemic regions and up to 25% in non-endemic areas. This type is less radiosensitive and is not associated with EBV infection. Types II and III are non-keratinizing carcinomas; Type II is differentiated and represents around 15% of cases, while Type III is undifferentiated, comprising approximately 80% of cases in endemic regions. Type III is strongly linked to EBV, is the most radiosensitive, and has the best prognosis with appropriate treatment. Types II and III are often grouped together as non-keratinizing NPC and predominate in endemic areas.

Staging (AJCC 8th Edition)

The T-staging system for NPC is based on the extent of local tumor invasion. T1 tumors are confined to the nasopharynx or extend to the oropharynx or nasal cavity. T2 tumors show parapharyngeal extension. T3 tumors invade the skull base or paranasal sinuses, while T4 tumors demonstrate intracranial extension, cranial nerve involvement, or invasion into the hypopharynx, orbit, or parotid gland. The N-staging for NPC is unique compared to other head and neck cancers, relying on the laterality and anatomical location of involved lymph nodes relative to the caudal border of the cricoid cartilage rather than size criteria. Notably, retropharyngeal node involvement is classified as N1, unlike in other head and neck cancers where it may be considered N3. Treatment recommendations vary by stage: Stage I (T1N0) is treated with radiation therapy alone, while stages II through IVA require concurrent chemoradiation, with or without induction or adjuvant chemotherapy.

Radiation Therapy

Dose and Fractionation

The gross tumor volume (GTV), including both primary tumor and involved nodes, is treated with a total dose of 70 Gy delivered in 33 to 35 fractions, equating to approximately 2.0 to 2.12 Gy per fraction. High-risk clinical target volumes (CTV) receive 60 to 63 Gy using a simultaneous integrated boost (SIB) technique, with a fraction size equivalent to 1.8 Gy. Low-risk or elective CTVs are treated to 54 to 56 Gy, also using SIB. The entire course of radiation typically spans about seven weeks.

Target Delineation

GTV

The GTV-primary encompasses all visible tumor identified on MRI, including T1 post-contrast and T2 sequences. This includes the nasopharyngeal mass itself, any skull base invasion, parapharyngeal extension, and intracranial involvement. The GTV-nodal includes all pathologic lymph nodes detected on imaging. MRI is essential for accurate GTV delineation because it is superior to CT in visualizing skull base involvement, parapharyngeal space extension, and intracranial disease.

CTV

The high-risk CTV includes the GTV plus a 5 to 10 mm margin, covering the entire nasopharynx, involved parapharyngeal space, and areas of skull base erosion with an appropriate margin. The intermediate-risk CTV encompasses adjacent high-risk nodal levels, retropharyngeal nodes, the clivus, pterygoid plates and fossae, the floor of the sphenoid sinus, and the posterior nasal cavity. Elective nodal CTV includes bilateral levels II through V and retropharyngeal nodes, which are routinely included due to their high risk of involvement. Level IB is included if level II nodes are involved. Retropharyngeal nodes carry a risk of occult involvement exceeding 60% and must always be included in the radiation field.

Critical Anatomic Considerations

Coverage of the skull base must include the clivus, foramen ovale, foramen lacerum, and cavernous sinus if involved. The parapharyngeal space is a common route for lateral tumor extension and requires full coverage. Intracranial extension involving the temporal lobe and cavernous sinus necessitates generous radiation coverage while maintaining strict dose constraints to minimize toxicity to the temporal lobes.

IMRT Planning Considerations

IMRT or volumetric modulated arc therapy (VMAT) is mandatory for NPC treatment due to the complex target geometry, which often resembles a horseshoe shape wrapping around critical structures like the brainstem and spinal cord. Sparing of the parotid glands is crucial, with the goal of keeping the mean dose to the contralateral parotid below 26 Gy and bilateral sparing when feasible. The temporal lobes should be limited to a dose of less than 65 to 69 Gy to reduce the risk of temporal lobe necrosis. The brainstem maximum dose should not exceed 54 Gy on the surface and 60 Gy in small volumes. The cochlea should receive a mean dose below 45 Gy, especially important given the ototoxicity risk from concurrent cisplatin chemotherapy. The optic chiasm and nerves should be limited to a maximum dose of 54 Gy, and doses to the mandible and temporomandibular joint should be minimized to reduce the risk of trismus and osteoradionecrosis.

Systemic Therapy

Concurrent Chemotherapy

Concurrent chemotherapy with cisplatin at a dose of 100 mg/m² every three weeks for three cycles during radiation is the backbone of treatment for stage II to IVA NPC, as established by the Intergroup 0099 trial. An alternative regimen involves weekly cisplatin at 40 mg/m² during radiation, which offers comparable efficacy with better tolerability.

Induction Chemotherapy

Induction chemotherapy before concurrent chemoradiation is increasingly accepted for locoregionally advanced NPC, particularly in patients with bulky nodal disease or high EBV DNA levels. Phase III data from China demonstrated that gemcitabine plus cisplatin (GP) induction chemotherapy improves overall survival and progression-free survival. Another regimen, docetaxel plus cisplatin and 5-fluorouracil (TPF), has also shown benefit in some trials.

Adjuvant Chemotherapy

The Intergroup 0099 trial included adjuvant chemotherapy with cisplatin and 5-fluorouracil for three cycles following concurrent chemoradiation. However, compliance with adjuvant chemotherapy is often poor, with only about 60% of patients completing all three cycles. Meta-analyses support the benefit of concurrent chemotherapy but show less clear advantages for the adjuvant phase. Consequently, many centers have shifted their focus from adjuvant to induction chemotherapy.

Immunotherapy

NPC has demonstrated responsiveness to PD-1 inhibitors, with trials such as JUPITER-02 and CAPTAIN-1st showing benefits of immunotherapy in recurrent or metastatic disease. Multiple ongoing trials are evaluating the integration of immunotherapy with concurrent chemoradiation in the definitive treatment setting.

EBV DNA Monitoring

Baseline plasma EBV DNA levels correlate with tumor burden and stage. Detectable EBV DNA in plasma 4 to 12 weeks after treatment strongly predicts disease recurrence. The NRG HN001 trial is investigating risk-adapted treatment strategies based on post-treatment EBV DNA levels. This biomarker may eventually guide treatment de-escalation in patients with undetectable post-treatment EBV DNA or intensification in those with persistently elevated levels.

Outcomes

For stage I NPC, radiation therapy alone achieves a five-year overall survival (OS) rate exceeding 95%. Stage II disease treated with concurrent chemoradiation yields a five-year OS of 85 to 90%. For stages III to IVA, concurrent chemoradiation with or without induction chemotherapy results in a five-year OS of 70 to 80%. Locoregional recurrence rates with modern IMRT range from 5 to 15% and have been declining over time. Despite improvements in local control, distant metastasis remains the dominant pattern of failure, occurring in 15 to 25% of patients, with bone, lung, and liver being the most common sites.

<image>An axial MRI (T1 post-contrast) at the level of the nasopharynx showing a nasopharyngeal carcinoma extending into the left parapharyngeal space. Treatment planning contours are overlaid: GTV-primary (red) encompasses the enhancing nasopharyngeal mass and parapharyngeal extension; CTV-high risk (orange) includes the entire nasopharynx and parapharyngeal space with margin; CTV-elective (blue) includes bilateral retropharyngeal and cervical nodal levels. The bilateral parotid glands are contoured as avoidance structures (yellow). IMRT isodose lines show 70 Gy (red), 63 Gy (orange), and 56 Gy (blue) dose levels wrapping conformally around the brainstem and spinal cord.</image>

<image>A coronal view of an NPC IMRT plan showing the dose distribution from the skull base through the neck. The high-dose region (70 Gy) covers the nasopharynx and skull base while the dose gradient protects the temporal lobes superiorly. Bilateral neck levels II-V are covered by the intermediate dose (56 Gy). The parotid glands are partially spared. Annotations identify the retropharyngeal nodal region, cavernous sinus, and the SIB dose levels.</image>

Key Clinical Pearls

MRI is indispensable for accurate staging and target delineation in NPC, as CT alone tends to underestimate critical tumor extensions such as skull base invasion, parapharyngeal spread, and intracranial involvement. Therefore, diagnostic MRI should always be fused with planning CT scans. IMRT is not just preferred but mandatory for NPC treatment because the complex target geometry—characterized by the nasopharynx wrapping around the brainstem and spinal cord and the need for bilateral neck coverage with parotid sparing—cannot be adequately achieved with conventional 3D conformal radiation therapy. Retropharyngeal lymph nodes must always be included in the clinical target volume regardless of their appearance on imaging, given that occult involvement exceeds 60%. Temporal lobe necrosis is the most devastating late toxicity associated with NPC IMRT; it is dose-dependent and typically manifests 2 to 10 years post-treatment. Strict adherence to temporal lobe dose constraints, specifically limiting the dose to 1 cubic centimeter (D1cc) to less than 65 Gy, is essential to minimize this risk. Plasma EBV DNA functions as a "liquid biopsy" for NPC and should be utilized at baseline, during treatment, and in surveillance to guide clinical decision-making. Weight loss and nutritional decline are nearly universal during NPC treatment, so early prophylactic gastrostomy tube placement should be considered for patients with advanced disease, alongside weekly nutritional monitoring to optimize patient outcomes.

References

• Al-Sarraf M et al. "Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099." J Clin Oncol. 1998;16(4):1310-1317.
• Lee AW et al. "Evolution of treatment for nasopharyngeal cancer -- success and setback in the intensity-modulated radiotherapy era." Radiother Oncol. 2014;110(3):377-384.
• Zhang Y et al. "Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma." N Engl J Med. 2019;381(12):1124-1135.
• Lee N et al. "Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225." J Clin Oncol. 2009;27(22):3684-3690.
• Blanchard P et al. "Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis." Lancet Oncol. 2015;16(6):645-655.

Read this lecture as Markdown